



■ Phase 2b: placebo/dupilumab   ■ Phase 2b: dupilumab/dupilumab   ■ QUEST: placebo/dupilumab   ■ QUEST: dupilumab/dupilumab

## High-dose ICS


### (A) Exposed population



### (B) ≥150 eosinophils/μL at PSBL



### (C) ≥300 eosinophils/μL at PSBL



### (D) FeNO ≥25 ppb at PSBL

